ClinicalTrials.gg
CompletedNCT07749872KAP TBUpdated Aug 6, 2026

KAP TB in Senior Management Officials of Companies With Increased Silica Exposure

An observational study in TB - Tuberculosis, Silicosis and Occupational Exposure, sponsored by Centre for Infectious Disease Research in Zambia. Completed at 1 site in Zambia. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Centre for Infectious Disease Research in Zambia · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
118
Sex
All
01

Study summary

The study was designed as a descriptive cross-sectional survey conducted between February and October 2022. Senior management officials were targeted because of their role in workplace policy and oversight. The sample was drawn from companies registered under the Zambia Chamber of Commerce and Industry (ZACCI), focusing on those with known silica dust exposure. Each company was asked to provide one or two senior officials to participate. A total of 118 individuals completed the survey.

Data collection was carried out using a self-administered electronic questionnaire developed in line with WHO recommendations for TB KAP surveys. The questionnaire contained 28 mandatory closed-ended questions: 7 on knowledge, 8 on attitudes, and 13 on practices (with 5 practice questions excluded from scoring as they were programmatic). Responses were validated by three medical doctors, and scoring was based on correct answers. Knowledge, attitude, and practice scores were categorized into "poor" or "good" using mean or median cutoffs depending on distribution. Logistic regression was applied to explore associations between participant characteristics and KAP outcomes.

Read the detailed description

Tuberculosis (TB) continues to pose a significant global health burden, particularly among individuals in the economically productive age group of 15-64 years. In Zambia, 85% of TB cases occur in this demographic, underscoring the dual public health and socio-economic impact. The risk is compounded in industries with high exposure to crystalline silica dust, such as mining, construction, drilling, cement, brick, tile, glass, and ceramics manufacturing. Prolonged inhalation of silica dust can lead to silicosis, a condition that increases the risk of TB three to four times compared to individuals without silicosis. Even without silicosis, silica exposure alone elevates TB risk. Poor workplace conditions, including overcrowding and inadequate ventilation, further exacerbate transmission risks.

Recognizing these occupational hazards, the study aimed to assess the knowledge, attitudes, and practices (KAP) of senior management officials in companies with high silica exposure. These officials play a critical role in shaping workplace policies and interventions, making their understanding and attitudes toward TB prevention and management essential for effective workplace health strategies.

The research was conducted as a descriptive cross-sectional study between February and October 2022 in Lusaka and Southern provinces of Zambia. These provinces were selected due to their concentration of industries associated with silica dust exposure. The study focused on senior management officials, defined as either the most senior staff in an organization or heads of divisions/departments, given their influence on workplace health policies.

The sample population was drawn from the Zambia Chamber of Commerce and Industry (ZACCI), an umbrella organization representing businesses across all sectors. ZACCI advocates for workplace legislation and a conducive business environment. Companies known to produce silica dust were identified under categories including mining, construction, cement manufacturing, brick and tile manufacturing, and glass and ceramic manufacturing. The sampling frame included 1 mining company, 73 construction companies, 1 cement company, 9 brick/tile companies, and 10 glass/ceramic companies.

Each company was asked to nominate at least one senior official to complete the questionnaire, with a maximum of two responses per company. This ensured representation across industries while maintaining focus on individuals with policy-making authority.

Data were collected using a multiple-choice electronic questionnaire developed in accordance with WHO guidelines for TB KAP surveys. The questionnaire was self-administered in English via Google Forms and contained 28 mandatory closed-ended questions:

  • Knowledge: 7 questions
  • Attitudes: 8 questions
  • Practices: 13 questions (with 5 excluded from scoring as they were programmatic) Of the 28 questions, 21 were multiple-choice, while 7 required a single best answer. The questionnaire was distributed via email, with three reminders sent to encourage participation. Due to low response rates from email reminders, physical follow-ups were conducted. Ultimately, participants completed the survey independently on tablets between June and November 2022.

Responses were validated by three medical doctors. A response was considered correct if at least two doctors agreed. This ensured accuracy and minimized bias in scoring. Responses marked as "don't know," "not sure," or "other" were treated neutrally with a score of 0. Ambiguous "other" responses were excluded from analysis.

Survey responses were stored on Google Forms, downloaded into a CSV file, and imported into Python (version 3.8) for recoding. The dataset was then analyzed using STATA (version 18.5). Descriptive statistics were used to summarize participant characteristics and categorical variables.

A scoring system was applied:

  • Knowledge: maximum of 17 points
  • Attitudes: maximum of 7 points
  • Practices: maximum of 14 points Correct responses scored 1, incorrect responses scored 0. Scores were categorized into "poor" or "good" based on mean or median cutoffs depending on distribution. Logistic regression was used to explore associations between participant characteristics (age, gender, industry, department) and KAP outcomes. Univariable analysis identified potential associations, followed by multivariable analysis to control for confounders. Variables with p-values above 0.05 were excluded unless only two variables remained significant, in which case the higher p-value variable was retained.
02

Conditions studied

  • TB - Tuberculosis
  • Silicosis
  • Occupational Exposure
  • Occupational Health

Keywords

  • TB
  • Tuberculosis
  • Knowledge
  • Attitude
  • Practice
  • Senior management
  • Silicosis
  • Silica Dust
  • non mining companies
03

In context

Latent Tuberculosis

199 studies on the registry are indexed under Latent Tuberculosis; 48 are open to participants now.

This study's enrollment of 118 is below the median of 260 across 82 observational studies indexed under Latent Tuberculosis.

Browse Latent Tuberculosis studies →

Lead sponsor

Centre for Infectious Disease Research in Zambia is the lead sponsor of 41 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The sample population was drawn from the Zambia Chamber of Commerce and Industry (ZACCI), an umbrella organization representing businesses across all sectors. ZACCI advocates for workplace legislation and a conducive business environment. Companies known to produce silica dust were identified under categories including mining, construction, cement manufacturing, brick and tile manufacturing, and glass and ceramic manufacturing. The sampling frame included 1 mining company, 73 construction companies, 1 cement company, 9 brick/tile companies, and 10 glass/ceramic companies.

Each company was asked to nominate at least one senior official to complete the questionnaire, with a maximum of two responses per company. This ensured representation across industries while maintaining focus on individuals with policy-making authority.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Companies known to produce silica dust
  • members of ZACCI
  • current active senior management role

Exclusion criteria

Exclusion Criteria:

  • none silica producing companies
  • junior staff
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
118 participants (actual)
Patient registry
No

Groups and cohorts

  • Senior management from companies known to produce silica dust

    Categories including mining, construction, cement manufacturing, brick and tile manufacturing, and glass and ceramic manufacturing.

06

What researchers measure

Primary outcomes

  1. Knowledge, attitudes, and practices (KAP) scores related to tuberculosis among senior management of manufacturing, construction, and mining companies associated with exposure to silica dust.

    Descriptive Cross - sectional study

    Time frame: Conducted between February 2022 to October 2022

07

Study locations

1 site
  • CIDRZ
    Lusaka, Lusaka Province 10101, Zambia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Oct 2022, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2026
First posted
Aug 6, 2026
StartActual
Feb 2, 2022
Primary completionActual
Oct 15, 2022
CompletionActual
Feb 28, 2023
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07749872
Lead sponsor
Centre for Infectious Disease Research in Zambia
Responsible party
Sponsor
First posted
Aug 6, 2026
Start date
Feb 2, 2022
Primary completion
Oct 15, 2022
Completion
Feb 28, 2023
Last update
Aug 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion